Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether pentoxifylline changes burning sensation (VAS 0-100) compared with spirulina (very low certainty).
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Rajendran 2006 (pentoxifylline 14 vs multivitamins 15): reported increased interincisal distance in the pentoxifylline group but no baseline data, so change could not be determined; excluded from meta-analysis.
1 study · 29 participants
GRADE not reported
Difficulty in speech (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Pentoxifylline led to lower difficulty in speech (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
1 finding from 1 review
Difficulty in swallowing (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Pentoxifylline led to lower difficulty in swallowing (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether pentoxifylline changes maximal mouth opening (interincisal distance) compared with placebo or no active treatment (very low certainty).
2 findings from 1 review
Severity of oral/mucosal burning pain/sensation · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Rajendran 2006 concluded the intervention reduced pain, but pain intensity evaluations were inadequately defined and from interview data, making mean scores difficult to interpret.
1 study · 29 participants
GRADE not reported
Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether pentoxifylline changes burning sensation (VAS 0-100) compared with placebo or no active treatment (very low certainty).
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Pentoxifylline may leads to lower maximal mouth opening (interincisal distance) compared with spirulina (low certainty).
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Pentoxifylline showed no clear difference in oral mucositis (moderate to severe) compared with no treatment; GRADE not reported.
1 finding from 1 review
Pain, number of ulcers, ulcer-free days and ulcer size · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
A single trial at high risk of bias compared pentoxifylline 400 mg three times daily (n=14) with placebo (n=12). No statistically significant differences were reported for pain, number of ulcers and ulcer-free days at…
1 study · 26 participants
GRADE not reported
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Patients receiving pentoxifylline reported more adverse events than those in the placebo group but this was not statistically significant (69% reported adverse effects: dizziness, headaches, stomach upset, increased…
1 study · 26 participants
GRADE not reported